cgmp

T-0156 is a novel, potent and selective phosphodiesterase type 5 inhibitor that inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) with low affinity for PDE6, PDE1, PDE2, PDE3 and PDE4.

Sulmazole (AR-L 115-BS) is a small molecule Sulmazole is a small molecule cGMP-PDE inhibitor.Sulmazole is a competitive inhibitor of A1 adenosine receptors.Sulmazole has been shown to improve cardiac index, low pulmonary capillary wedge pressure, and can be used in the study of heart failure.Sulmazole is a small molecule cGMP-PDE inhibitor.

Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

AP-C5 is a compound with selective inhibition of guanosine 3',5' cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), with a Pic50 value of 7.2 for cGMP, and can be used in the study of diarrheal diseases.

TP-10 is a selective inhibitor of PDE10A against other PDEs with IC50 of 0.8 nM.

Ataciguat (HMR-1766) (HMR-1766) is a potent and specific soluble guanylate cyclase (sGC) activator.

Vardenafil dihydrochloride (Levitra) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

MBP146-78 is a potent and selective inhibitor of cGMP-dependent protein kinases (cGMP-dependent protein kinases).

Kuraridine is measured against cGMP PDE5 to identify potent cGMP specific phosphodiesterase type 5 inhibitory constituents.

Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analog that preferentially activates cGMP-dependent protein kinase (PKG). It inhibits [3H]-arachidonic acid release in human platelets stimulated by gamma thrombin and can induce peripheral analgesia by activating ATP-sensitive K+ channels.

8-Bromo-cGMP sodium is a PKG activator, a membrane-permeable analog of cGMP. 8-Bromo-cGMP sodium has pain-relieving and vasodilatory effects, significantly inhibits Ca2+ macroscopic currents, and inhibits high K+-stimulated insulin release.

PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.

8-Nitro-cGMP is a unique cytoprotective mediator which inhibits oxidative stress. 8-Nitro-cGMP is also a probe of the protein S-guanylation.

cGMP-HTL, an autophagy-targeting chimera (AUTAC), consists of a HT-ligand, a linker, and a Cys-S-cGMP (autophagy tag), designed to enhance K63-linked ubiquitination of mitochondria. This novel clearance strategy features a degradation tag (guanine derivatives) and a specific warhead, facilitating targeted degradation [1].

Cys-C-cGMP serves as an autophagy tag for AUTACs (autophagy-targeting chimeras). It enhances K63-linked ubiquitination of mitochondria within HeLa cells [1].

Guanosine 2',3'-cyclic phosphate triethylamine, commonly known as 2′,3′-cGMP triethylamine, is an active compound utilizable in numerous research investigations [1].

8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.

8-Pcpt-cGMP acts as an agonist for cyclic nucleotide-gated (CNG) channels with an EC50 of 0.5 μM and exhibits good membrane permeability. This compound is utilized in research to explore the role of CNG channels in visual and olfactory signal transduction.

8-pCPT-cGMP-AM (8-(4-Chlorophenylthio)-cGMP-AM) is a highly membrane-permeable prodrug of the PKG agonist 8-pCPT-cGMP, designed to enhance membrane permeability of cGMP. It is converted into its active form within the cell via esterase hydrolysis, thus activating PKG. This compound is utilized to investigate the role of cGMP signaling in neural plasticity and memory formation.

2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium functions as an inhibitor of cyclic GMP-specific phosphodiesterases (cyclic GMP-specific phosphodiesterase), exhibiting an IC50 value of 35 µM. This compound effectively inhibits the hydrolysis of phosphodiesterases that use cAMP or cGMP as substrates in a Ca2+-dependent manner.

8-NBD-cGMP is a fluorescent analog of cyclic guanosine monophosphate (cGMP), acting as an effective membrane-permeable fluorescent activator for cGMP-dependent protein kinase isozymes I α and I β. This compound exhibits negligible fluorescence in aqueous solutions, but emits intense fluorescence in hydrophobic environments (such as hydrophobic protein binding sites).

8-Br-PET-cGMP is an agonist of type I cyclic GMP-dependent protein kinase (cGKI), which promotes the dimerization and activation of the catalytic activity of cGKI by binding to its regulatory domain. This compound is utilized to investigate the role of the cGMP signaling pathway in cell growth, vasodilation, and smooth muscle cell functions.